Nov 17, 2025 06:15AM
Oct 24, 2025 08:30AM
Oct 24, 2025 08:30AM
Sep 22, 2025 08:01AM
Sep 22, 2025 08:00AM
Aug 12, 2025 07:00AM
May 14, 2025 04:05PM Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights
Apr 15, 2025 07:40AM
Mar 3, 2025 04:01PM
Mar 3, 2025 04:01PM
Nov 18, 2024 07:09AM
Nov 18, 2024 07:00AM
Nov 15, 2024 04:07PM
Nov 15, 2024 04:05PM Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements
Nov 4, 2024 04:39PM
Aug 13, 2024 04:47PM
Aug 12, 2024 04:05PM
Aug 1, 2024 08:01AM
Aug 1, 2024 08:00AM
Jul 17, 2024 02:45AM
May 9, 2024 04:05PM Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights
Mar 18, 2024 04:05PM
Feb 8, 2024 07:02AM
Feb 8, 2024 07:00AM
Nov 9, 2023 04:05PM
Nov 4, 2023 05:54PM
Sep 26, 2023 04:05PM
Sep 26, 2023 04:05PM Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data from the LUNA Phase 2 Trial
Aug 10, 2023 04:05PM
May 25, 2023 06:30AM
May 25, 2023 06:30AM
May 18, 2023 09:00AM
May 11, 2023 04:05PM
Apr 24, 2023 05:29AM
Apr 23, 2023 01:00PM Adverum Biotechnologies Presents Nonclinical Data at the 2023 ARVO Annual Meeting Supporting Potential for Staggered Bilateral Administration of Ixo-vec
Apr 18, 2023 08:00AM
Mar 30, 2023 04:08PM
Mar 30, 2023 04:05PM
Nov 10, 2022 04:05PM
Aug 11, 2022 04:05PM
Jul 15, 2022 08:33AM
Jul 15, 2022 08:32AM Adverum Biotechnologies Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After a Single IVT Injection of ADVM-022 (Ixo-vec) in the OPTIC Study in Wet AMD
Jul 6, 2022 04:07PM
Jul 6, 2022 04:05PM
May 19, 2022 08:00AM
May 12, 2022 04:05PM
May 2, 2022 04:30PM
Apr 6, 2022 04:05PM
Apr 6, 2022 04:05PM Adverum Biotechnologies Proceeds with IND Amendment for ADVM-022 Phase 2 Trial in Wet AMD After Receiving Requested Type C Meeting Feedback from the FDA
Mar 29, 2022 04:05PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All